Analysts Set Aemetis, Inc. (NASDAQ:AMTX) Price Target at $12.95

Aemetis, Inc. (NASDAQ:AMTX) has been assigned an average rating of “Moderate Buy” from the five brokerages that are presently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $12.95.

Several brokerages recently issued reports on AMTX. StockNews.com upgraded Aemetis to a “sell” rating in a research report on Wednesday. HC Wainwright reissued a “buy” rating and issued a $28.00 target price on shares of Aemetis in a report on Monday, December 23rd.

Aemetis Trading Down 3.3 %

Shares of AMTX opened at $2.04 on Friday. The company’s 50 day simple moving average is $2.78 and its 200-day simple moving average is $2.85. The firm has a market cap of $101.46 million, a PE ratio of -0.90 and a beta of 1.44. Aemetis has a 12-month low of $2.01 and a 12-month high of $7.03.

Aemetis (NASDAQ:AMTX) last issued its quarterly earnings data on Tuesday, November 12th. The specialty chemicals company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.09. The business had revenue of $81.44 million for the quarter, compared to analysts’ expectations of $77.79 million. During the same period in the previous year, the business posted ($0.59) earnings per share. As a group, equities research analysts forecast that Aemetis will post -2.07 EPS for the current fiscal year.

Hedge Funds Weigh In On Aemetis

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Bank of New York Mellon Corp boosted its stake in shares of Aemetis by 29.6% in the fourth quarter. Bank of New York Mellon Corp now owns 91,880 shares of the specialty chemicals company’s stock valued at $247,000 after buying an additional 20,961 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Aemetis in the fourth quarter valued at $87,000. Clear Harbor Asset Management LLC purchased a new stake in shares of Aemetis during the 4th quarter worth $44,000. Barclays PLC boosted its position in shares of Aemetis by 274.6% during the 3rd quarter. Barclays PLC now owns 47,496 shares of the specialty chemicals company’s stock worth $109,000 after purchasing an additional 34,816 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Aemetis by 7.7% during the 3rd quarter. Geode Capital Management LLC now owns 924,293 shares of the specialty chemicals company’s stock worth $2,126,000 after purchasing an additional 66,031 shares during the period. Institutional investors and hedge funds own 27.02% of the company’s stock.

Aemetis Company Profile

Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.